% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Niersmann:147522,
      author       = {C. Niersmann and M. Carstensen-Kirberg and H. Maalmi and B.
                      Holleczek and M. Roden and H. Brenner$^*$ and C. Herder and
                      B. Schöttker$^*$},
      title        = {{H}igher circulating omentin is associated with increased
                      risk of primary cardiovascular events in individuals with
                      diabetes.},
      journal      = {Diabetologia},
      volume       = {63},
      number       = {2},
      issn         = {1432-0428},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DKFZ-2019-02576},
      pages        = {410-418},
      year         = {2020},
      note         = {Diabetologia. 2020 Feb;63(2):410-418#LA:C070#},
      abstract     = {Higher concentrations of the adipokine omentin are
                      associated with lower levels of cardiometabolic risk factors
                      in experimental and cross-sectional studies, but with higher
                      risk of type 2 diabetes and cardiovascular diseases in
                      population-based cohort studies. However, it is unknown
                      whether high omentin concentrations are associated with
                      increased risk of cardiovascular events in people with
                      established diabetes. Therefore, the present study
                      investigated the association between serum omentin
                      concentrations and the risk of cardiovascular events in
                      individuals with diabetes.This prospective study was based
                      on participants of the German ESTHER cohort with diabetes
                      and without previous cardiovascular event. The ESTHER cohort
                      consists of individuals aged 50-75 years at baseline who
                      were recruited by their general practitioners. After
                      exclusion of individuals with serum C-reactive protein ≥10
                      mg/l (≥95.24 nmol/l), the final analysis population
                      consisted of 933 individuals. At baseline, serum omentin
                      concentrations were measured by ELISA. Cox regression models
                      were fitted to estimate HRs and their corresponding $95\%$
                      CIs for associations of omentin tertiles with a composite
                      endpoint of cardiovascular events and separately with
                      incident myocardial infarction, stroke and cardiovascular
                      death.During 14 years of follow-up, 228 individuals
                      experienced a primary cardiovascular event (myocardial
                      infarction, stroke or cardiovascular death). After
                      comprehensive adjustment for age, sex, BMI, metabolic and
                      lifestyle factors and medication use, HRs $(95\%$ CIs) for
                      the 2nd and 3rd tertile of omentin compared with the 1st
                      tertile were: 1.24 $(95\%$ CI 0.86, 1.79) and 1.63 (1.15,
                      2.32) (ptrend = 0.005) for the composite cardiovascular
                      endpoint; 1.39 (0.78, 2.47) and 1.71 (0.98, 2.99) (ptrend =
                      0.065) for incident myocardial infarction; 1.40 (0.78, 2.53)
                      and 2.05 (1.17, 3.58) (ptrend = 0.010) for incident stroke;
                      and 1.43 (0.85, 2.40) and 1.72 (1.04, 2.83) (ptrend = 0.040)
                      for cardiovascular death. Effect estimates and p values were
                      almost unaltered after additional adjustment for
                      adiponectin.Higher omentin concentrations are associated
                      with an increased risk for cardiovascular events in
                      individuals with diabetes after adjustment for multiple
                      cardiovascular risk factors. Given data from preclinical
                      studies, it appears possible that this association reflects
                      a compensatory, but insufficient upregulation of omentin
                      concentrations as a response to stimuli that increase
                      cardiovascular risk.},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {323 - Metabolic Dysfunction as Risk Factor (POF3-323)},
      pid          = {G:(DE-HGF)POF3-323},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31705160},
      doi          = {10.1007/s00125-019-05017-2},
      url          = {https://inrepo02.dkfz.de/record/147522},
}